Explore

Trendline Trendline
UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies

UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies

UCB Acquires Candid Therapeutics for $2 Billion to Expand T-Cell Engager Therapies
Trendline Trendline
UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with T-cell Engagers

UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with T-cell Engagers

UCB to Acquire Candid Therapeutics, Expanding Immunology Pipeline with T-cell Engagers
Trendline Trendline
UCB Acquires Candid Therapeutics in $2.2 Billion Autoimmune Deal

UCB Acquires Candid Therapeutics in $2.2 Billion Autoimmune Deal

UCB Acquires Candid Therapeutics in $2.2 Billion Autoimmune Deal
Trendline Trendline
UCB Acquires Candid Therapeutics to Enhance Immunology Pipeline with T-cell Engagers

UCB Acquires Candid Therapeutics to Enhance Immunology Pipeline with T-cell Engagers

UCB Acquires Candid Therapeutics to Enhance Immunology Pipeline with T-cell Engagers
Trendline Trendline
ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates
Trendline Trendline
Lunai Bioworks Secures $20 Million to Enhance CNS Drug Delivery and Neurotherapeutics

Lunai Bioworks Secures $20 Million to Enhance CNS Drug Delivery and Neurotherapeutics

Lunai Bioworks Secures $20 Million to Enhance CNS Drug Delivery and Neurotherapeutics
Trendline Trendline
Bambusa Therapeutics Completes Enrollment for Atopic Dermatitis Drug Trial

Bambusa Therapeutics Completes Enrollment for Atopic Dermatitis Drug Trial

Bambusa Therapeutics Completes Enrollment for Atopic Dermatitis Drug Trial
Trendline Trendline
Merck Ends Development of TROP ADC Amidst Strategic Pipeline Adjustments

Merck Ends Development of TROP ADC Amidst Strategic Pipeline Adjustments

Merck Ends Development of TROP ADC Amidst Strategic Pipeline Adjustments
Trendline Trendline
Molecular Partners' MP0317 Shows Promise in Tumor-Localized CD40 Activation, Phase 2 Trial Initiated

Molecular Partners' MP0317 Shows Promise in Tumor-Localized CD40 Activation, Phase 2 Trial Initiated

Molecular Partners' MP0317 Shows Promise in Tumor-Localized CD40 Activation, Phase 2 Trial Initiated
Trendline Trendline
Bicycle Therapeutics Advances Cancer Drug Development with Promising Clinical Data

Bicycle Therapeutics Advances Cancer Drug Development with Promising Clinical Data

Bicycle Therapeutics Advances Cancer Drug Development with Promising Clinical Data
Trendline Trendline
Contineum Therapeutics Reports Positive Results from PIPE-791 Phase 1b Trial for Chronic Pain

Contineum Therapeutics Reports Positive Results from PIPE-791 Phase 1b Trial for Chronic Pain

Contineum Therapeutics Reports Positive Results from PIPE-791 Phase 1b Trial for Chronic Pain
Trendline Trendline
Esperion Therapeutics to be Acquired by ARCHIMED in $1.1 Billion Deal

Esperion Therapeutics to be Acquired by ARCHIMED in $1.1 Billion Deal

Esperion Therapeutics to be Acquired by ARCHIMED in $1.1 Billion Deal